Siliphos in Advanced Hepatocellular Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01129570|
Recruitment Status : Completed
First Posted : May 24, 2010
Last Update Posted : November 25, 2013
Milk thistle is an herbal drug that may have some liver protection properties and may reduce inflammation in the liver. It may also have anticancer effects. However milk thistle is not approved by the Food and Drug Administration for any medical purpose in the United States.
It has not been used in patients with liver cancer previously, to our knowledge, but there have been many studies of its use in patients with hepatitis and cirrhosis. Some of these studies have shown that milk thistle may help reduce elevated liver function tests.
Siliphos is a derivative of milk thistle that can be absorbed better than some other types of milk thistle. The investigators would like to perform a study to identify doses of siliphos that are safe to take in advanced liver cancer and to identify positive or negative side effects this compound may have. The investigators will be using this information in future studies to see if siliphos can be used as a therapy in patients with advanced liver cancer to reduce elevated liver function tests.
|Condition or disease||Intervention/treatment||Phase|
|Advanced Hepatocellular Carcinoma||Drug: Silybin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Trial of Siliphos in Patients With Advanced Hepatocellular Carcinoma|
|Study Start Date :||February 2010|
|Primary Completion Date :||June 2013|
|Study Completion Date :||June 2013|
|Experimental: Siliphos - dose escalation||
4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
- The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma [ Time Frame: Weeks 1, 3, 6, 9, and 12 ]
- Mean intra-patient percent change in AST, ALT and total serum bilirubin levels [ Time Frame: From baseline to 3 months ]Fasting morning blood samples collected at baseline, weeks 1, 3, 6, 9, and 12
- Quality of life as measured by the FACT-hepatobiliary questionnaire [ Time Frame: From baseline to 3 months ]Questionnaire administered at baseline, weeks 1, 6, and 12
- Plasma concentrations of silybinin, silybinin B, silibinin glucoronide, and silibinin sulfate [ Time Frame: From baseline to 3 months ]Fasting morning blood samples collected at baseline, weeks 1, 3, 6, 9, and 12
- Mean intra-patient percent change in serum concentrations of CRP, IGF-1, and IGFBP-3 [ Time Frame: From baseline to 3 months ]Fasting morning blood samples collected at baseline, weeks 1, 3, 6, and 12
- Tumor response as measured by RECIST criteria and AFP concentrations [ Time Frame: From baseline to 3 months ]
Fasting blood samples collected at baseline, weeks 1, 3, 6, 9, and 12 for AFP concentrations.
MRI of abdomen/pelvis & CT of chest at baseline and week 12
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01129570
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|Principal Investigator:||Abby Siegel, MD, MS||Columbia University|